3. Results
Between January 1st and May 31st 2020, among patients hospitalised in the COVID-19 Units of Careggi University Hospital, Florence (Italy), clinicians requested a consultation for a total of 23 patients who experienced one or more ADRs.
All patients were Caucasian with a mean age of 76.1 (SD Table 2 ).
Table 3 shows a case-by-case description of evaluated ADR reports. One patient presented an elevation of transaminases, 3 patients experienced gastrointestinal (GI) ADRs (nausea, diarrhoea, vomiting and GI pain), 18 patients showed cardiovascular (CV) ADRs (ECG QT prolongation), one patients presented a prolongation of the QT interval along with symptoms of major depression, and one patient reported psychotic symptoms. The 19 patients who experienced an ECG QT prolongation, showed a mean prolongation of QT interval of 496.1 (SD ±14.4) msec (Table 2 ).
Table 4 shows all moderate and major DDIs observed in our sample between COVID-19 treatments and patients’ concomitant medications. The application of tools for interactions revealed that all patients presented at least one DDI. Among 82 different DDIs, 53 (64.4%) were moderate, and 32 (39%) increased the risk of QT prolongation. Many others DDIs (n=112) were identified between medications other than COVID-19 treatments (Supplementary Table 1 ).